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The S protein (S) binds to the attack complex ofcom-
plement (CSb-9) in plasma preventing cytolysis. Using
immunofluorescence microscopy, the authors deter-
mined the distribution of S in human renal tissue and
its relationship to C5b-9, immunoglobulins, C3, albu-
min, and fibronectin. They examined normal and dis-
eased human kidney tissue from patients with several
forms of glomerulonephritis, diabetic nephropathy,
and arterionephrosclerosis. S and CSb-9 were found in
all diseased tissues; their amounts and distribution di-
rectly correlated with severity and location ofinjury. S
THE CYTOLYTIC MEMBRANE attack complex,
C5b-9(m), develops during complement activation
on lipid bilayers. This amphiphilic macromolecule
inserts into lipid membranes via lipophilic binding
sites. The S-protein (S) is an acid glycoprotein found
in human plasma.' Binding ofS to the attack complex
of complement during its assembly in plasma results
in the formation of a cytolytically inactive complex,
SC5b-9.2 In vitro, S covers exposed apolar surfaces on
fully assembled C5b-9(m), thereby converting an am-
phiphilic structure into a hydrophilic macromole-
cule.3 Whether this in vitro effect of S on C5b-9(m)
occurs in vivo is not known.
C5b-9 has been immunohistochemically located in
renal tissues from patients with immune- and nonim-
mune-mediated renal disease.4'5 In selected experi-
mental models of immune mediated glomerulone-
phritis, the attack complex plays an important
pathogenic role.6'7 Detection ofthe complex in tissue
depends on antibodies that recognize neoantigens
present in the attack complex but not present on na-
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and C5b-9 were colocalized in all immune deposits and
in all injured glomeruli, tubular basement membranes,
and vessel walls. Other than within immune deposits, S
and CSb-9 were usually not colocalized with C3. This
study demonstrates that S is deposited in areas oftissue
injury and thus may participate in the pathogenesis of
renal damage. Because in tissue S and CSb-9 are always
associated, the attack complex in tissue must either be
derived from the circulation as SCSb-9 or it must be
capable of binding S after the formation in situ of
CSb-9. (AmJ Pathol 1987, 127:182-190)
tive complement components. All of these reagents
recognize C5b-9 incorporated in SC5b-9 as well as
C5b-9(m).8 Thus the immunohistochemically identi-
fied complex may be present as a result oflocal com-
plement activation or deposition from the circula-
tion. The possibility that SC5b-9 is deposited from the
circulation must be considered because it has been
detected in the plasma of patients with active
glomerulonephritis.9"10
We sought to determine the presence and location
of the S protein in normal and diseased human renal
tissue. Because the S protein is the only immuno-
Supported by National Institute of Health Grants
AM34855 and AM30701, funds from the Veterans Admin-
istration, and the Thomas R. Arthur Trust. Dr. Falk is a
Hartford Foundation Fellow.
Accepted for publication December 4, 1986.
Address reprint requests to Ronald J. Falk, MD, Depart-
ment ofMedicine, Division ofNephrology, North Carolina
Memorial Hospital, 3034 Old Clinic Bldg. 226H, Chapel
Hill, NC 27514.
PROTEIN IN RENAL DISEASE 183
histochemical difference between SCSb-9 and
C5b-9(m), we compared the distribution of S with
that of C5b-9, C3, and IgG, IgM, and IgA. Because
many anionic serum proteins bind to the glomerular
capillary wall," we compared the distribution of S
with that of similarly anionic albumin. These studies
were performed in human renal tissue having no
pathologic evidence of disease and in a variety of im-
mune and nonimmune mediated lesions.
Materials and Methods
Antibodies
The characterization of the monoclonal antibody
to a neoantigen of C9 present in C5b-9(m) and
SC5b-9 has been previously documented.4 The
monoclonal antibody to S which was made from pu-
rified S was a kind gift from Cytotech (San Diego,
Calif). This monoclonal antibody is specific for puri-
fied S, and it is also specific for S incorporated into
SC5b-9. The immunoglobulin fraction of a poly-
clonal goat antibody to human S was absorbed with
S-deficient human serum2 and then rhodaminated by
conventional techniques. The monoclonal and poly-
clonal anti-S antibodies had identical staining pat-
terns in human renal tissue. Polyclonal fluorescein-
ated antibodies to human C3, IgG, IgM, and IgA were
obtained from Meloy (Springfield, Va), and to C5
from Atlantic Antibody (Scarborough, Me). Fluores-
ceinated anti-human albumin, human plasma-ab-
sorbed goat anti-mouse Ig (heavy- and light-chain-
specific) and human plasma-absorbed rabbit
anti-goat Ig (heavy- and light-chain-specific) were ob-
tained from Cappel Laboratories (Malvern, Pa). A
monoclonal antibody to fibronectin was also used.'2
Tissue Sections
Renal tissue was obtained for this investigation as
part of clinically indicated diagnostic studies. We ex-
amined 6 renal biopsy specimens with no morpho-
logic lesions on light, immunofluorescence, or elec-
tron microscopy; 7 with minimal change disease; 11
with membranous glomerulopathy; 11 with IgA
glomerulonephritis (GN); 4 with postinfectious GN
(characteristic clinical history and typical epimemn-
branous humps along the glomerular basement
membrane [GBMJ); 8 with proliferative systemic
lupus nephritis; and 3 with Type I membranoproli-
ferativeGN (MPGN). In addition, 10 cases ofdiabetic
nephropathy were examined in patients with known
diabetes, clinical nephrosis, and the absence of other
glomerular disease. Six cases of arterionephroscler-
osis and 4 cases of transplant allograft rejection were
also studied.
Immunofluorescence Studies
For immunofluorescence microscopy, blocks of
tissue were snap-frozen in liquid nitrogen, embedded
in OCT, and stored at -70 C until sectioned. Some
specimens were held in Michell's transport medium
prior to freezing. Four-micrometer sections were
stained with the antibodies described above.4"3 Prep-
arations were examined with the use ofa Lietz Ortho-
plan microscope equipped for incident light fluores-
cence microscopy. Immunofluorescence studies were
performed on serial or step sections for evaluation of
the relative positions of the antigens. The intensity
and distribution of immunostaining for each protein
were assessed on an arbitrary scale of0-4+. Specific
co-localization of the neoantigen of C9 and S was
performed by sequentially incubating the tissue with
anti-neoantigen ofC9, fluoresceinated anti-mouse Ig,
and rhodaminated polyclonal anti-S antibody.
Results
The amount of immunostaining for S protein in
renal tissues was directly proportional to the degree of
morphologic injury assessed by light-microscopic
evaluation (Figure 1). There were negligible amounts
ofS in cases ofno lesion and minimal change disease
(MCD). In contrast, the intensity ofanti-S immunor-
eactivity was most marked in tissues in which there
were plentiful immune deposits (systemic lupus ery-
thematosus [SLE] orMPGN) or large areas ofmesan-
gial expansion and glomerulosclerosis (diabetes mel-
litus).
Along glomerular capillary walls, S was not detect-
able in cases of no lesion and MCD (Figure 1). In
diseases in which there were minimal alterations of
the GBM (IgA GN, allograft rejection, and arterio-
sclerotic disease), S was linearly distributed in a trace
to 1+ intensity along the endothelial surface of the
GBM. In this instance, the pattern of albumin im-
munoreactivity was similar to that of S, but with a
much greater intensity than S. The linear distribution
of S along the GBM was most marked in cases of
diabetes mellitus (Figure 2A). In membranous ne-
phropathy, S was present in immune deposits within
and along the epithelial surface of the GBM (Figure
3A and B). In SLE GN, MPGN, and postinfectious
GN, S was localized in subepithelial and subendothe-
lial immune deposits.
In the mesangium, S was only minimally present
in the hilar region of no lesion and MCD cases. The
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Figure 1-Comparison of S, neoantigen of C9 (NC9), C5 and C3 immuno-
reactivity in glomerular capillaries and mesangium, arterioles, arteries, and
tubular basement membranes (TBM) in renal tissues without lesions and
immune- and nonimmune-mediated human renal diseases.
intensity of anti-S staining increased with advancing
mesangial expansion and glomerulosclerosis. This
was best exemplified in diabetic nephropathy and ar-
terionephrosclerosis. S was present in mesangial im-
mune deposits in immune-mediated glomerular dis-
eases. It was intensely localized in the mesangium in
IgA (Figure 4A), SLE, postinfectious and Type I
MPGN.
In arterioles and arteries, S was present throughout
vessel walls (Figure 5A). There was relatively less S
immunoreactivity in no lesion and MCD cases when
compared with the high intensity and homogeneous
distribution seen in all other disease groups. Along
tubular basement membranes, S was present in a focal
granular pattern (Figure 6). The extent ofits distribu-
tion and the intensity ofanti-S staining directly corre-
lated with the degree of tubulointerstitial injury.
The presence ofC5b-9 was determined by the colo-
calization ofC5 with the neoantigen ofC9 present in
the attack complex. These two antigens were always
found together in all loci and in all disease groups.
This observation has been previously reported, as well
as the observation that all other constituents of the
attack complex are present with CS and neoantigen of
C9.4 Thus the colocalization of C5 with the neoanti-
gen of C9 immunohistochemically identifies the
C5b-9 complex.
When S was linearly distributed along the GBM,
C5b-9 was not present. However, in all other loci and
in all disease groups S and C5b-9 were colocalized. In
immune mediated disease, S and C5b9 were ubiqui-
tously found together in immune deposits. The inten-
sity of immunostaining for S, C5 and neo-C9 were
similar (Figure 1). S and C5b-9 were colocalized, for
example, in intra- and epimembranous immune de-
posits in membranous nephropathy (Figure 3); along
with C3 and IgA in the mesangium ofIgAGN (Figure
4B); in subepithelial and subendothelial immune de-
posits in SLE; in epimembranous humps in postin-
fectious GN; and in MPGN. Wherever S and C5b-9
were present in immune deposits, C3 was present,
albeit with lesser intensity of immunoreactivity.
In both nonimmune and immune mediated dis-
eases, S and C5b-9 were always colocalized in regions
of mesangial expansion and glomerulosclerosis. In
these loci, C3 was not regularly present. This was espe-
cially notable in vessel walls (Figure 5) and along tu-
bular basement membranes where S and C5b-9 were
almost invariably deposited together in the absence of
C3 or immunoglobulin.
The S protein is an adhesive protein which binds to
a variety of surfaces. The gene sequence for the S
protein has recently been established and found to be
homologous with vitronectin.'4 Vitronectin is an ad-
hesive extracellular matrix protein similar in nature
to fibronectin.'5 The distribution ofvitronectin in tis-
sues has been compared with that offibronectin.'6We
sought to determine whether the localization offibro-
nectin was similar to that of S. Fibronectin was
present in all cases studied in a 2-3 + intensity in the
mesangium, in a trace distribution along the glomer-
ular capillary walls, and in vessel walls usually along
the luminal surface. It was not present along tubular
basement membranes. Therefore, the distribution of
fibronectin was entirely unlike that ofS and C5b-9 in
all of the diseases studied (Figure 3H).
Discussion
The distribution of the S protein and the intensity
of its immunoreactivity were evaluated in normal
human renal tissues and in immune and nonimmune
diseases. The relative amounts of S, as assessed by
AJP * April 1987
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Figure 2-Step sections of a gbmerulus and arteroe from a patient with diabeticglomerulosclerosis. (X360) A-lmmunostaining for S protein showing
staining of glomerular mesangium and basement membrares and the arteriole. 8-Immunostaining for C9 neoantigen showing granular staining of
glomerular masangium and the arteriole.
immunohistochemical techniques, were directly pro-
portional to the severity of injury. The amount of S
ranged from undetectable in no lesion cases to a 4+
intensity in areas of injured glomeruli, tubules, and
blood vessel walls.
The presence of S in a linear pattern along the
GBM, primarily in nonimmune diseases, was similar
to that seen with albumin. S has isoelectric points in
the range pH 4.75-5.25.1, Melvin et allI have ob-
served that many anionic proteins bind along the glo-
merular capillary wall, whereas proteins with isoelec-
tric points greater than pH 6.0 do not. This process is
accentuated in certain diseases, especially diabetic ne-
phropathy. The linear distribution of S in this loca-
tion may be attributable to an electrical charge inter-
action. In these loci, S was not associated with C5O9.
In all immune-mediated renal lesions, S and C5b-9
were localized together with similar intensity in im-
mune deposits. Within immune deposits, S and
C5b9 were present with C3 and immunoglobulin.
Presumably in these areas the attack complex is lo-
cally generated by classical or alternative pathway ac-
tivation. S and CSb-9 were also colocalized in dis-
eased mesangium, injured tubular basement mem-
branes, and vessel walls in all diseases (immune- and
non-immune-mediated). In these loci, in contrast to
our findings within immune deposits, S and C5b-9
were usually not colocalized with C3. This was espe-
cially true along tubular basement membranes and in
vessel walls.
The invariable colocalization ofS with C5b9 indi-
cates that C5b-9(m) does not exist in tissues without
association ofS. This contention is based on the speci-
ficity of the antibodies employed in this study. The
antibody to a neoantigen ofC9 binds to activated C9
and not to native complement components, nor does
it bind to any intermediate complex in attack com-
plex formation.4 The anti-S monoclonal binds to S
and S incorporated into SC5b-9. It does not bind to
complement components C5 through C9.
The complex of S in tissue with C5b-9 could be
derived from two sources. Either SC5b9 formed in
the blood compartment deposits in tissues, or
C5b-9(m) is locally formed by complement activation
Vol. 127 * No. I
Figure 3-Immunofluorescence microscopy of step sections of a glomerulus from a patient with idiopathic membranous glomerulopathy. (X340) A and
B-Same section dual stained respectively for S protein (rhodaminated polyclonal goat anti-S protein) and C9 neoantigen (fluoresceinated second antibody to
mosu monociGonal anti-lg neoantugen). C-H-Step sections immunostained with monoclonal anti-S protein (C), monoclonal anti-C9 neoantigen (D),polyclonal anti-C3 (E), polyclonal anti-C5 (F), polyclonal anti-albumin (G), and monoclonal anti-fibronectin (H).
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Figure 4-Step sections of a gkomerular segment from a patient with IgA nephropathy immunostainec tor ti protein (A) showing intense mesangial immune
deposit staining and low-intensity basement membrane staining and immunostained for C9 neoantigen (B), showing intense staining of immune deposits.
(X 1 000)
and then complexed to S. Both processes may occur.
The presence ofSC5b-9 in the plasma ofpatients with
lupus nephritis9 and other immune-mediated dis-
eases10 raises the possibility of its deposition from the
circulation into tissue. Moreover, the observation ofS
and C5b-9 localization without association of C3 in
vessel walls suggests that the circulatingcomplex may
be deposited, rather than genented by tocl comple-
ment activation. However,SS must also be-complexing
with the membrane attack complex- after local com-
plement activation. The strongest support for this
contention is derived from our observation of S and
C5b-9 colocalization in intra- and epimembranous
deposits in 11 cases ofmembranous glomerulopathy.
This disease process is putatively caused by "in situ"
immune complex formation.17 Because C5b-9 is pre-
sumably generated by classical pathway activation in
the immune deposit, S must be bound to theMAC "in
situ" as well. Moreover, the large size ofSC5b-9 (ap-
proximately 1 million daltons) renders unlikely the
possibility of the filtration of the intact molecule
across the glomerular capillary wall.
The in vivo observation ofS binding to preformed
C5b-9 has an in vitro experimental basis.3 When S
binds to isolated and purified C5b-9(m), the complex
changes from an amphiphilic to a hydrophilic struc-
ture by the covering ofexposed apolar surfaces. This
complex has been given the name SC5b9(m). As a
corollary, the hydrophilic-amphiphilic transition also
may occur when S is proteolytically cleaved from
C5b9, which thereby generates a cytolytically active
complex.18'19 This immunohistochemical study
would support these in vitro observations, suggesting
that S binds to preformed C5b-9(m) in vivo.
The gene sequences for S and vitronectin have a
high degree ofhomology.'4 Vitronectin is an extracel-
lular matrix molecule to which cells adhere. Fibronec-
tin, laminin, and collagens may have similar capabili-
ties.1I We were concerned that the distribution ofS in
the kidney has been similar to other adhesive pro-
teins. Comparative studies of S with fibronectin and
the known distribution oflaminin and collagen types
I through V in normal and diseased human renal
tissues12 20 exclude this concern.
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Figure 5-Step sections of an arteriole from a patient with arterionephrosclerosis showing immunostaining for S protein (A) and C3 (B). (X600)
I
Whether S without association of C5b9 plays a
separate role in renal damage is not discernible from
these studies. However, S may participate in the mod-
ulation of the damaging effects of CSb-9(m) by in-
creasing the solubility of this macromolecule. More-
over, SC5b-9 may be deposited in tissue from the
blood. Whether this fluid-phase form of the attack
complex has a pathogenic effect once deposited in
tissue is the subject of ongoing investigation.
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